Novo Nordisk, a leading Danish biotech company, emerged as a major player in the pharmaceutical industry, primarily with the weight-loss drug Wegovy. Its remarkable valuation of $570 billion showcases a prosperous link between Danish research policies and commercial success. With substantial contributions to Denmark's tax revenue, including almost $4 billion from corporate taxes and $3.8 billion from income taxes, the company serves as a model for effective utilization of public funding in science. Nobel laureate Morten Meldal emphasizes that Novo Nordisk exemplifies a broader trend of science-driven success in Denmark's economy connected to its research framework.
Novo Nordisk is the result of Denmark's system-its success is directly attributable to how our society operates: We have high taxes, but those taxes result in huge tax-exempt industrial foundations funding science and creating opportunities for both academic and industrial success.
That success has led to major interest in how Denmark's model of combined strong fundamental and applied research paid off so spectacularly and whether it can be replicated.
Collection
[
|
...
]